Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Body Composition × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Polycystic Ovary Syndrome 1 Oligomenorrhea 1 Motor Activity 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1 Insulin Resistance 1 Hyperandrogenism 1 Hodgkin Disease 1 Hirsutism 1 Fatigue 1 Diabetes Mellitus, Type 1 1 Depression 1 Congenital Abnormalities 1 Breast Neoplasms 1

Interventions

Trastuzumab 556 Paclitaxel 513 Cyclophosphamide 491 Docetaxel 431 Capecitabine 372 Letrozole 336 Fulvestrant 292 Doxorubicin 262 Tamoxifen 245 Carboplatin 243 Anastrozole 211 Radiotherapy 201 exemestane 199 Epirubicin 180 Bevacizumab 178 palbociclib 170 Lapatinib 156 Vinorelbine 155 pertuzumab 152 Gemcitabine 151 pembrolizumab 146 Surveys and Questionnaires 124 Exercise 119 Magnetic Resonance Spectroscopy 117 eribulin 108 Albumin-Bound Paclitaxel 108 Fluorouracil 105 Blood Specimen Collection 103 130-nm albumin-bound paclitaxel 99 Everolimus 94

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04638712 2023-02-09

PROTECT-03

Institut de cancérologie Strasbourg Europe

Phase NA Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡